Neurology

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a...

The chief scientific officer at Alzheon discussed the mechanism of valiltramiprosate and new data on toxic amyloid oligomers presented at the recently...

The director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital gives clinicians insight on the reasons to attend the 2025 C...

Teva's fremanezumab gains FDA approval for pediatric migraine prevention, offering a vital treatment option for children aged 6-17.

The neurologist at Duke Health provided insights on how chronic demyelinating inflammatory polyneuropathy treatment is evolving toward biomarker-drive...

Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initi...

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specific...

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC...

Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing...